Immunogenicity of β-cells for autologous transplantation in type 1 diabetes

Christian Schuetz; James F Markmann

doi:10.1016/j.phrs.2015.03.003

Immunogenicity of β-cells for autologous transplantation in type 1 diabetes

Pharmacol Res. 2015 Aug:98:60-8. doi: 10.1016/j.phrs.2015.03.003. Epub 2015 Mar 20.

Authors

Christian Schuetz¹, James F Markmann²

Affiliations

¹ Islet Transplantation Laboratory, Division of Transplantation, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Thier 825, Boston, MA 02114, United States. Electronic address: [email protected].
² Islet Transplantation Laboratory, Division of Transplantation, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Thier 825, Boston, MA 02114, United States.

PMID: 25801943
DOI: 10.1016/j.phrs.2015.03.003

Abstract

The success of clinical islet transplantation calls for a broader application of this curative treatment for type 1 diabetes mellitus. The toxicity of immunosuppression, limited organ donor supply and high procedural costs are deterrents to expand this therapy to patients with uncomplicated diabetes. The use of pancreatic β-cell like cells derived from the patient's own induced pluripotent cells (iPSC) holds potential to overcome these barriers. In this review, we discuss the practicality of this regenerative medicine approach and existing evidence regarding the true immunogenicity of iPSC derived cells.

Keywords: Immune tolerance; Immunogenicity; Induced pluripotent stem cells; Islet transplantation; Pancreatic beta cells; Type 1 diabetes mellitus.

Publication types

Review

MeSH terms

Animals
Diabetes Mellitus, Type 1 / surgery*
Diabetes Mellitus, Type 1 / therapy
Humans
Insulin-Secreting Cells / immunology*
Insulin-Secreting Cells / transplantation*
Islets of Langerhans Transplantation
Pluripotent Stem Cells / transplantation
Transplantation, Autologous